AbbVie (ABBV)
173.37  +0.18 (0.10%)

AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments.

SummaryNewsPress ReleasesChartHistorical
Neurocrine Wins FDA Approval For Genetic Disorder Druginvestors.com
The company can launch within a week, says Chief Executive Kyle Gano.
Via Investor's Business Daily · December 13, 2024
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Foreverfool.com
Via The Motley Fool · December 12, 2024
Analyst Scoreboard: 19 Ratings For AbbViebenzinga.com
Via Benzinga · December 10, 2024
Check Out What Whales Are Doing With ABBVbenzinga.com
Via Benzinga · December 9, 2024
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Studybenzinga.com
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety.
Via Benzinga · December 9, 2024
Check Out What Whales Are Doing With ABBVbenzinga.com
Via Benzinga · December 4, 2024
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalystsbenzinga.com
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Via Benzinga · December 4, 2024
Spotlight on AbbVie: Analyzing the Surge in Options Activitybenzinga.com
Via Benzinga · November 29, 2024
(ABBV) - Analyzing AbbVie's Short Interestbenzinga.com
Via Benzinga · November 26, 2024
Market Whales and Their Recent Bets on ABBV Optionsbenzinga.com
Via Benzinga · November 25, 2024
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longerfool.com
Via The Motley Fool · December 3, 2024
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yieldsbenzinga.com
Via Benzinga · December 3, 2024
It’s Been A Tough Month For Healthcare Stockstalkmarkets.com
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.
Via Talk Markets · December 2, 2024
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Laterfool.com
Via The Motley Fool · December 1, 2024
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Foreverfool.com
Via The Motley Fool · November 30, 2024
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Incomefool.com
Via The Motley Fool · November 26, 2024
Unpacking the Latest Options Trading Trends in AbbViebenzinga.com
Via Benzinga · November 20, 2024
Where Will AbbVie Be in 5 Years?fool.com
Via The Motley Fool · November 19, 2024
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforcebenzinga.com
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
Via Benzinga · November 26, 2024
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buysfool.com
Via The Motley Fool · November 23, 2024
3 Dividend Stocks That Are Screaming Buys in Novemberfool.com
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
Via The Motley Fool · November 23, 2024
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setbackinvestors.com
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like.
Via Investor's Business Daily · November 22, 2024
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Fridaybenzinga.com
Via Benzinga · November 22, 2024
What To Do After The Worst Week For Healthcare Stocks Since March 2020?talkmarkets.com
The market  was quiet today but we should still expect some gains through year -end albeit a bit choppy.
Via Talk Markets · November 19, 2024
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dipfool.com
Via The Motley Fool · November 18, 2024